Korean biopharmaceutical company Genexine (KOSDAQ: 095700) reported on Wednesday that it has dosed the first patient in a phase 2 clinical trial using triple combination therapy in patients with recurrent/metastatic HNSCC.
This therapy is a combination of two of Genexine's proprietary drugs, GX-188E (a first-in-class therapeutic DNA vaccine), GX-I7 (a first-in-class long-acting interleukin 7), along with OpdivoR (nivolumab), a marketed PD-1 immune checkpoint inhibitor.
Professor Hye-Ryun Kim of the Department of Oncology at Yonsei Severance Hospital Cancer Center is leading the phase 2 clinical trial, which is being conducted in South Korea. The trial will evaluate the safety and efficacy in 21 patients with HPV-16 or 18-positive recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Endpoints assessed during the study include those related to safety and efficacy, including the overall rate of response, Genexine stated.
The company added that its proprietary immuno-oncology drug GX-I7 is being developed globally as a first-in-class drug. It amplifies absolute lymphocyte counts, therefore, increasing the number of T cells and has a mechanism to penetrate them into the tumour microenvironment. Another innovative drug being used in the triple combination is GX-188E, an anticancer DNA vaccine that has a mechanism of preferentially targeting HPV antigens to dendritic cells.
Genexine is focused on the development and commercialisation of immunotherapeutics and next-generation long-acting biologics. Its primary technology platforms are Therapeutic DNA vaccine technology and hyFcR fusion technology.
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Lipocine doses first cohort in LPCN 1154 study
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates